DateTitle 
November 19, 2012POZEN to Present at the 24th Annual Piper Jaffray Healthcare ConferencePrinter Friendly Version
November 15, 2012POZEN Announces Positive Results for the PA8140-102 Bioavailability StudyPrinter Friendly Version
November 08, 2012POZEN Reports Third Quarter 2012 Financial Results and Positive PA32540 Clinical UpdatesPrinter Friendly Version
November 06, 2012POZEN Presents Positive PA32540 Pivotal Phase 3 Data at the American Heart Association Scientific Sessions 2012Printer Friendly Version
October 29, 2012POZEN Announces November 8th Webcast of Third Quarter 2012 Results and November 6th Presentation of Phase 3 Results for PA32540 at AHA’s Scientific Sessions 2012Printer Friendly Version
October 01, 2012POZEN Patents Upheld in Treximet Patent Litigation AppealPrinter Friendly Version
August 29, 2012POZEN Announces PA32540 Provides Superior Antiplatlet Effects over a Standard of Care Regimen in a Phase 1 Study (“Co-Rx”)Printer Friendly Version
August 27, 2012POZEN to Present at the 2012 Stifel Nicolaus Healthcare ConferencePrinter Friendly Version
August 23, 2012POZEN Provides Update on Its PA Program and Results of Its Type A Meeting with the FDAPrinter Friendly Version
August 01, 2012POZEN Reports PA32540 / PA8140 Updates and Second Quarter 2012 Financial ResultsPrinter Friendly Version
July 18, 2012POZEN Announces August 1, 2012 Webcast of Second Quarter 2012 ResultsPrinter Friendly Version
June 26, 2012POZEN Receives Patent on PA Products for Treatment of Cardiovascular Disease and OsteoarthritisPrinter Friendly Version
June 20, 2012POZEN Announces FDA Response to Its Phase 1, PA32540 Bioequivalence Study AnalysesPrinter Friendly Version
June 07, 2012POZEN to Present at the 2012 Wells Fargo Securities Healthcare ConferencePrinter Friendly Version
May 22, 2012POZEN to Present at the Jefferies 2012 Global Healthcare ConferencePrinter Friendly Version
May 19, 2012PA32540 Provides Faster Gastric Acid Reduction Than Enteric-Coated Omeprazole (40 mg)Printer Friendly Version
May 08, 2012POZEN Announces Licensing Deal with Desitin Arzneimittel GMBH for MT 400 Migraine Treatment in 29 European CountriesPrinter Friendly Version
May 01, 2012POZEN Reports PA32540 / PA8140 Updates and First Quarter 2012 Financial ResultsPrinter Friendly Version
April 18, 2012POZEN Announces May 1, 2012 Webcast of First Quarter 2012 ResultsPrinter Friendly Version
March 22, 2012POZEN Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of PA32540Printer Friendly Version
March 01, 2012POZEN to Present at the 24th Annual ROTH ConferencePrinter Friendly Version
February 28, 2012POZEN Reports Fourth Quarter & Year End 2011 ResultsPrinter Friendly Version
February 14, 2012POZEN Announces February 28, 2012 Webcast of Fourth Quarter & Year End 2011 ResultsPrinter Friendly Version
February 02, 2012POZEN’s Digital Advisory Board to Speak at Annual ePharma SummitPrinter Friendly Version
February 01, 2012Preventive Aspirin Use Less Than Optimal in Stroke Survivors Despite Clinical GuidelinesPrinter Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.